Results 1 to 10 of about 4,742,503 (345)
Canadian Medical Association Journal, 2021 Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy.
V. Makker +6 more
semanticscholar +9 more sources
The Lancet, 2022 Endometrial cancer is the most common gynaecological cancer in high income countries and its incidence is rising globally. Although an ageing population and fewer benign hysterectomies have contributed to this trend, the growing prevalence of obesity is the major underlying cause.
E. J. Crosbie +5 more
semanticscholar +6 more sources
Best Practice & Research Clinical Obstetrics & Gynaecology, 2012 Endometrial carcinoma is the most common gynaecological malignancy in the Western world. The standard management of endometrial carcinoma is total hysterectomy and bilateral salpingo-oophorectomy with or without pelvic and para-aortic lymph-node dissection.
Vivek, Arora, Michael A, Quinn
+10 more sources
The Lancet, 2016 Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus.
Morice, P. +4 more
+7 more sources
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
New England Journal of Medicine, 2023 BACKGROUND Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
M. Mirza +30 more
semanticscholar +1 more source
FIGO staging of endometrial cancer: 2023
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023 Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009.
Jonathan S Berek +8 more
semanticscholar +1 more source
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
New England Journal of Medicine, 2023 BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander +26 more
semanticscholar +1 more source
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
New England Journal of Medicine, 2022 BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously ...
V. Makker +23 more
semanticscholar +1 more source
Reproductive Factors and Endometrial Cancer Risk Among Women
JAMA Network Open, 2023 Key Points Question Are reproductive factors and endometrial cancer risk associated among individuals in East Asia? Findings In this pooled cohort study of 332 625 women including 1005 endometrial cancer cases from 13 Asian cohort studies, late menarche,
R. Katagiri +36 more
semanticscholar +1 more source
Immunotherapy in endometrial cancer
International Journal of Gynecological Cancer, 2023 The Cancer Genome Atlas (TCGA) endometrial cancer data expanded our knowledge about the role of different immunotherapeutic approaches based on molecular subtypes.
Haider Mahdi +2 more
semanticscholar +1 more source